Bank of New York Mellon’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $60.3K | Sell |
68,491
-820
| -1% | -$870 | ﹤0.01% | 4230 |
|
|
2026
Q1 | $41.9K | Hold |
69,311
| – | – | ﹤0.01% | 4151 |
|
|
2025
Q4 | $53.4K | Buy |
69,311
+40,018
| +137% | +$36.1K | ﹤0.01% | 4137 |
|
|
2025
Q3 | $29.6K | Hold |
29,293
| – | – | ﹤0.01% | 4150 |
|
|
2025
Q2 | $39K | Hold |
29,293
| – | – | ﹤0.01% | 4095 |
|
|
2025
Q1 | $34.9K | Sell |
29,293
-2
| -0% | -$3 | ﹤0.01% | 4068 |
|
|
2024
Q4 | $47.8K | Hold |
29,295
| – | – | ﹤0.01% | 4077 |
|
|
2024
Q3 | $112K | Hold |
29,295
| – | – | ﹤0.01% | 4000 |
|
|
2024
Q2 | $85.8K | Sell |
29,295
-69,555
| -70% | -$223K | ﹤0.01% | 4039 |
|
|
2024
Q1 | $391K | Sell |
98,850
-8,892
| -8% | -$45.8K | ﹤0.01% | 3664 |
|
|
2023
Q4 | $535K | Sell |
107,742
-1,084
| -1% | -$5.39K | ﹤0.01% | 3514 |
|
|
2023
Q3 | $550K | Sell |
108,826
-745
| -0.7% | -$4.08K | ﹤0.01% | 3497 |
|
|
2023
Q2 | $551K | Buy |
109,571
+66,039
| +152% | +$432K | ﹤0.01% | 3531 |
|
|
2023
Q1 | $268K | Sell |
43,532
-19,849
| -31% | -$162K | ﹤0.01% | 3796 |
|
|
2022
Q4 | $837K | Buy |
63,381
+25,231
| +66% | +$178K | ﹤0.01% | 3280 |
|
|
2022
Q3 | $113K | Hold |
38,150
| – | – | ﹤0.01% | 4173 |
|
|
2022
Q2 | $139K | Sell |
38,150
-607
| -2% | -$2.89K | ﹤0.01% | 4162 |
|
|
2022
Q1 | $240K | Hold |
38,757
| – | – | ﹤0.01% | 4144 |
|
|
2021
Q4 | $314K | Hold |
38,757
| – | – | ﹤0.01% | 4068 |
|
|
2021
Q3 | $577K | Hold |
38,757
| – | – | ﹤0.01% | 3726 |
|
|
2021
Q2 | $486K | Buy |
38,757
+4,856
| +14% | +$37.9K | ﹤0.01% | 3784 |
|
|
2021
Q1 | $154K | Sell |
33,901
-2,463
| -7% | -$9.91K | ﹤0.01% | 4107 |
|
|
2020
Q4 | $78K | Hold |
36,364
| – | – | ﹤0.01% | 4110 |
|
|
2020
Q3 | $85K | Hold |
36,364
| – | – | ﹤0.01% | 3974 |
|
|
2020
Q2 | $73K | Sell |
36,364
-1
| -0% | -$1 | ﹤0.01% | 3936 |
|
|
2020
Q1 | $26K | Buy |
+36,365
| New | +$63K | ﹤0.01% | 4036 |
|
|
2019
Q1 | – | Sell |
-780
| Closed | -$5K | – | 4237 |
|
|
2018
Q4 | $5K | Hold |
780
| – | – | ﹤0.01% | 4213 |
|
|
2018
Q3 | $13K | Hold |
780
| – | – | ﹤0.01% | 4224 |
|
|
2018
Q2 | $16K | Sell |
780
-2,933
| -79% | -$61.2K | ﹤0.01% | 4185 |
|
|
2018
Q1 | $88K | Buy |
3,713
+833
| +29% | +$224K | ﹤0.01% | 4084 |
|
|
2017
Q4 | $540K | Sell |
2,880
-9
| -0.3% | -$1.81K | ﹤0.01% | 3590 |
|
|
2017
Q3 | $620K | Sell |
2,889
-6
| -0.2% | -$1.24K | ﹤0.01% | 3476 |
|
|
2017
Q2 | $594K | Sell |
2,895
-164
| -5% | -$32.3K | ﹤0.01% | 3524 |
|
|
2017
Q1 | $557K | Buy |
3,059
+5
| +0.2% | +$990 | ﹤0.01% | 3512 |
|
|
2016
Q4 | $764K | Buy |
3,054
+466
| +18% | +$106K | ﹤0.01% | 3407 |
|
|
2016
Q3 | $539K | Buy |
2,588
+324
| +14% | +$64.2K | ﹤0.01% | 3499 |
|
|
2016
Q2 | $457K | Buy |
2,264
+1,147
| +103% | +$203K | ﹤0.01% | 3584 |
|
|
2016
Q1 | $204K | Buy |
1,117
+155
| +16% | +$27.7K | ﹤0.01% | 3782 |
|
|
2015
Q4 | $240K | Buy |
+962
| New | +$310K | ﹤0.01% | 3810 |
|
Other funds holding PDSB
IWA
TWP
ACM
DC
Bank of New York Mellon's PDSB Position: Q2 2026 in Review
Bank of New York Mellon reduced its PDS Biotechnology (PDSB) stake by 1.2% in Q2 2026, selling an estimated $870 and leaving 68,491 shares worth $60.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4230.
Bank of New York Mellon first reported a position in PDSB in Q4 2015 and has held it in 39 quarters since. The position peaked at $837K in Q4 2022. 16 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.
- Bank of New York Mellon held 68,491 shares of PDS Biotechnology worth $60.3K as of Q2 2026.
- Bank of New York Mellon sold 820 PDS Biotechnology shares in Q2 2026, an estimated $870.
- PDS Biotechnology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4230 holding.
- Bank of New York Mellon first reported a position in PDS Biotechnology in Q4 2015 and has held it in 39 quarters since.
- Bank of New York Mellon's PDS Biotechnology position peaked at $837K in Q4 2022.
- 16 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.